China Botanic Pharmaceutical (CBP)
China Botanic Pharmaceutical Revenues: 28.14M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBP Revenues Rankings
| Overall | 26th percentile | 3244 of 4425 |
| Sector | 50th percentile | 231 of 470 in Healthcare |
| Industry | 71st percentile | 38 of 132 in Biotechnology |
CBP Revenues Range, Past 5 Years
| Minimum | 9.264M | Jul 2010 |
| Maximum | 28.14M | Jan 2012 |
| Average | 17.36M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CBP related companies
CBP News
in $CBP for a trade on this article about chinese herbal cures in CBP on article http://stks.co/3Etg
about 53 days ago by super_trades
about 53 days ago by super_trades
China Botanic Pharmaceutical (CBP) Reports Q1 Earnings of $0.33/Share; Reaffirms Outlook
Mar 19, 7:03AM Street Insider
Mar 19, 7:03AM Street Insider
China Botanic Schedules Conference Call to Discuss Fiscal Year 2012 First Quarter Results
Mar 15, 5:46PM PR Newswire
Mar 15, 5:46PM PR Newswire
China Botanic Schedules Conference Call to Discuss Fourth Quarter and Fiscal Year 2011 Results
Jan 30, 12:34PM PR Newswire
Jan 30, 12:34PM PR Newswire
China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair
Dec 27, 8:00AM PR Newswire
Dec 27, 8:00AM PR Newswire
China Botanic develops new Siberian Ginseng polysaccharide extract powder
Dec 13, 8:07AM theflyonthewall.com
Dec 13, 8:07AM theflyonthewall.com
China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder
Dec 13, 8:00AM PR Newswire
Dec 13, 8:00AM PR Newswire
China Botanic Pharmaceutical (CBP) Increases Total Members on Board to 5 with Addition of Mr. Zack Zibing Pan
Oct 18, 8:15AM Street Insider
Oct 18, 8:15AM Street Insider
China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
Oct 18, 8:00AM PR Newswire
Oct 18, 8:00AM PR Newswire
China Botanic Hosts Symposium on Research of Polysaccharide Peptide and Natural Innovative Drugs
Sep 27, 8:00AM PR Newswire
Sep 27, 8:00AM PR Newswire
China Botanic Pharmaceutical (CBP) Reports Q3 Earnings of $0.07; Affirms Outlook
Sep 15, 6:29AM Street Insider
Sep 15, 6:29AM Street Insider
China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results
Sep 15, 6:00AM PR Newswire
Sep 15, 6:00AM PR Newswire
China Botanic Schedules Conference Call to Discuss FY 2011 Third Quarter Results
Sep 09, 8:04AM PR Newswire
Sep 09, 8:04AM PR Newswire
BBQ Trade Suggests Summer is Not Over | via @harmongreg http://stks.co/86W $COW $HNZ $CBP
about 263 days ago by chartly
about 263 days ago by chartly
BBQ Trade Suggests Summer is Not Over | via @harmongreg http://stks.co/82p $COW $HNZ $CBP
about 263 days ago by STNet
about 263 days ago by STNet
BBQ Trade Suggests Summer is Not Over http://stks.co/7lW $COW $HNZ $CBP
about 264 days ago by harmongreg
about 264 days ago by harmongreg
China Botanic enters research cooperation with Key Lab of Forest Plant Ecology
Sep 01, 8:10AM FlyOnTheWall
Sep 01, 8:10AM FlyOnTheWall
China Botanic Pharmaceutical Enters into Research Cooperation with Key Laboratory of Forest Plant Ecology
Sep 01, 8:00AM PR Newswire
Sep 01, 8:00AM PR Newswire
China Botanic granted China patent for Siberian Ginseng extraction process
Jun 30, 9:07AM FlyOnTheWall
Jun 30, 9:07AM FlyOnTheWall
China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
Jun 30, 8:00AM PR Newswire
Jun 30, 8:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBP | 0.56 | +0.01 | +1.82% | 20.85M |
| CBOU | 11.61 | +0.25 | +2.20% | 243.23M |
| CBOE | 25.24 | -0.15 | -0.59% | 2.241B |
| CBNJ | 8.19 | -0.03 | -0.36% | 109.01M |
| CBMX | 0.92 | -0.04 | -4.17% | 9.844M |
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| BRS | 43.38 | -0.33 | -0.76% | 1.548B |
| BRO | 25.69 | -0.17 | -0.66% | 3.683B |
| BRN | 3.25 | +0.00 | +0.00% | 26.91M |
| BRLI | 20.38 | +0.04 | +0.20% | 569.62M |
